Position towards hypertensive patients undergoing treatment with drugs acting on the renin-angiotensin-aldosterone system and COVID-19
Keywords:
COVID-19; coronavirus; SARS-CoV-2; severe acute respiratory syndrome; arterial hypertension; renin angiotensin aldosterone system
References
1) O’Mara GJ. Could ACE inhibitors, and particularly ARBs, Increase susceptibility to COVID-19 infection? Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406. doi: 10.1136/bmj.m406.
2) Sriram K, Insel PA. Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence [preprint]. medRxiv. Posted Apr 20, 2020. doi: 10.1101/2020.03.25.20043927.
3) De Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. May 14, 2020. doi: 10.1016/S0140-6736(20)31030-8.
4) Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Med. 2005;11(8):875-9.
5) Imai Y, Kuba K, Rao S, Guo F, Guan V, Yang P, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112‐6. doi: 10.1038/nature03712.
6) Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017;21(1):305. doi: 10.1186/s13054-017-1882-z.
7) Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19 [published online 2020 May 1, and updated on May 8]. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.
8) Chung SC, Providencia R, Sofat R. Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom [published online 2020 May 8]. N Engl J Med. 2020;NEJMc2005396. doi: 10.1056/NEJMc2005396.
2) Sriram K, Insel PA. Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence [preprint]. medRxiv. Posted Apr 20, 2020. doi: 10.1101/2020.03.25.20043927.
3) De Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. May 14, 2020. doi: 10.1016/S0140-6736(20)31030-8.
4) Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Med. 2005;11(8):875-9.
5) Imai Y, Kuba K, Rao S, Guo F, Guan V, Yang P, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112‐6. doi: 10.1038/nature03712.
6) Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017;21(1):305. doi: 10.1186/s13054-017-1882-z.
7) Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19 [published online 2020 May 1, and updated on May 8]. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.
8) Chung SC, Providencia R, Sofat R. Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom [published online 2020 May 8]. N Engl J Med. 2020;NEJMc2005396. doi: 10.1056/NEJMc2005396.
Published
2020-09-16
How to Cite
1.
Blanco C, Bueno D, Lavenia G, Krämer C, Inserra F, Sivak L. Position towards hypertensive patients undergoing treatment with drugs acting on the renin-angiotensin-aldosterone system and COVID-19. Rev Nefrol Dial Traspl. [Internet]. 2020Sep.16 [cited 2024Dec.27];40(3):191-3. Available from: http://vps-1689312-x.dattaweb.com/index.php/rndt/article/view/531
Section
Editorial
Copyright (c) 2020 Revista de Nefrología, Diálisis y Trasplante
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
